Instituut voor Neuropathische Pijn
English articles Research & Development Calmare(R) Pain Therapy Treatment in neuropathy proceeds
| Calmare(R) Pain Therapy Treatment in neuropathy proceeds |
|
Calmare(R) Pain Therapy Treatment in neuropathy proceeds, as they raised new capital to provide financing for CTT to more aggressively sell its innovative Calmare(R) Pain Therapy Treatment, which treats chronic neuropathic and oncologic pain, both in the U.S. and internationally. The CEO John B. Nano remarked:
"Our Calmare Pain Therapy Treatment sales have been increasing each quarter, and we expect sales to grow more rapidly as doctors and their patients observe the growing body of evidence-based research that shows Calmare successfully treats the various types of oncologic and neuropathic pain suffered by millions of patients worldwide, including 75 million Americans who suffer from chronic pain. "Providing this new, non-invasive way to treat pain other than prescribing opioids such as morphine continues to be a key focus of our mission to improve the quality of life for patients. We expect to revolutionize how chronic pain is treated globally." Evidence shows Calmare pain therapy effectively treats chronic cancer pain (CCP) and is the only highly effective treatment for chemotherapy-induced peripheral neuropathy (CIPN) without harmful, adverse side effects," The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy. Jan M. Keppel Hesselink, MD, PhD, June 2010 |